GSK plc announced that the U.S. Food and Drug Administration has extended the review period of the new drug application, or NDA, for momelotinib by three months to provide time to review recently submitted data. The extended action date is September 16, 2023. “GSK is confident in the momelotinib NDA and looks forward to working with the FDA as they finalise their review. Momelotinib is not currently approved in any market,” the company stated.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on GSK: